Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BHSENASDAQ:FENCNASDAQ:GNFTNASDAQ:TVGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHSEBull Horn$9.97$9.63▼$11.19$61.14M-0.0168,771 shs1.18 million shsFENCAdherex Technologies$7.76-1.3%$6.95$3.96▼$8.72$216.94M0.495,279 shs76,976 shsGNFTGENFIT$3.89-3.8%$4.09$2.55▼$6.42$201.99M1.1510,684 shs2,759 shsTVGNSemper Paratus Acquisition$1.20$1.15$0.26▼$3.09$220.67M-0.695.06 million shs597,872 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHSEBull Horn0.00%0.00%0.00%0.00%0.00%FENCAdherex Technologies-1.27%-2.14%-6.39%+16.34%+16.69%GNFTGENFIT-3.26%-5.24%-10.89%+7.02%-6.39%TVGNSemper Paratus Acquisition0.00%-3.23%+1.69%+5.26%+50.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBHSEBull HornN/AN/AN/AN/AN/AN/AN/AN/AFENCAdherex Technologies2.0712 of 5 stars3.62.00.00.00.63.30.0GNFTGENFIT2.5227 of 5 stars3.55.00.00.02.80.00.0TVGNSemper Paratus Acquisition3.9302 of 5 stars3.54.00.00.02.32.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHSEBull Horn 0.00N/AN/AN/AFENCAdherex Technologies 3.25Buy$13.0067.53% UpsideGNFTGENFIT 3.00Buy$13.00234.62% UpsideTVGNSemper Paratus Acquisition 3.00Buy$7.10491.67% UpsideCurrent Analyst Ratings BreakdownLatest BHSE, TVGN, FENC, and GNFT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025TVGNSemper Paratus AcquisitionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.006/10/2025TVGNSemper Paratus AcquisitionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/27/2025TVGNSemper Paratus AcquisitionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/20/2025FENCAdherex TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.005/14/2025FENCAdherex TechnologiesCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $13.005/12/2025TVGNSemper Paratus AcquisitionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/29/2025TVGNSemper Paratus AcquisitionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/21/2025TVGNSemper Paratus AcquisitionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHSEBull HornN/AN/AN/A7.36($0.72) per shareN/AFENCAdherex Technologies$47.54M4.51$0.03 per share243.38($0.21) per share-36.95GNFTGENFIT$76.77M2.53$0.07 per share57.76$1.50 per share2.59TVGNSemper Paratus AcquisitionN/AN/AN/AN/A($0.09) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHSEBull Horn$15.23MN/A0.00N/AN/AN/A-119.46%9.08%N/AFENCAdherex Technologies-$440K-$0.51N/AN/AN/A-45.52%N/A-26.37%8/12/2025 (Estimated)GNFTGENFIT$1.63MN/A0.00N/AN/AN/AN/AN/A7/24/2025 (Estimated)TVGNSemper Paratus Acquisition-$13.73MN/A0.00∞N/AN/AN/A-934.56%8/4/2025 (Estimated)Latest BHSE, TVGN, FENC, and GNFT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025FENCAdherex Technologies-$0.12-$0.04+$0.08-$0.04$8.18 million$8.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHSEBull HornN/AN/AN/AN/AN/AFENCAdherex TechnologiesN/AN/AN/AN/AN/AGNFTGENFITN/AN/AN/AN/AN/ATVGNSemper Paratus AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHSEBull HornN/A0.130.13FENCAdherex TechnologiesN/A5.134.97GNFTGENFIT0.081.231.23TVGNSemper Paratus AcquisitionN/A0.350.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHSEBull Horn74.95%FENCAdherex Technologies55.51%GNFTGENFIT2.24%TVGNSemper Paratus AcquisitionN/AInsider OwnershipCompanyInsider OwnershipBHSEBull Horn36.60%FENCAdherex Technologies11.76%GNFTGENFIT4.20%TVGNSemper Paratus Acquisition73.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHSEBull Horn25.12 million3.24 millionNot OptionableFENCAdherex TechnologiesN/A27.60 million24.35 millionOptionableGNFTGENFIT12050.00 million47.90 millionNot OptionableTVGNSemper Paratus Acquisition3183.89 million49.21 millionN/ABHSE, TVGN, FENC, and GNFT HeadlinesRecent News About These CompaniesD. Boral Capital Reiterates "Buy" Rating for Semper Paratus Acquisition (NASDAQ:TVGN)June 20 at 2:51 AM | americanbankingnews.comSemper Paratus Acquisition's (TVGN) "Buy" Rating Reaffirmed at D. Boral CapitalJune 18 at 9:36 AM | marketbeat.comTevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target DiscoveryJune 18 at 8:30 AM | globenewswire.comTevogen BioJune 17, 2025 | thepharmaletter.comTevogen Bio Expands Headquarters To Support Growth In AI And Generics & Biosimilars InitiativesJune 12, 2025 | nasdaq.comTevogen Bio's (TVGN) Buy Rating Reaffirmed at D. Boral CapitalJune 11, 2025 | americanbankingnews.comTevogen Bio Expands Headquarters to Enhance R&D and Operational Efficiency with Support from MicrosoftJune 10, 2025 | nasdaq.comTevogen Bio doubles Warren HQ footprint for AI expansionJune 10, 2025 | njbiz.comAmbitious Tevogen makes expansion announcementJune 10, 2025 | thepharmaletter.comTevogen Bio (NASDAQ:TVGN) Given "Buy" Rating at D. Boral CapitalJune 10, 2025 | marketbeat.comRyan H. Saadi Sells 1,438,206 Shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) StockJune 10, 2025 | insidertrades.comInsider Selling: Tevogen Bio Holdings Inc. (NASDAQ:TVGN) CEO Sells 1,438,206 Shares of StockJune 9, 2025 | marketbeat.comTevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars InitiativesJune 9, 2025 | globenewswire.comtevogen bio expands office lease in new jersey with key amendmentJune 5, 2025 | investing.comTevogen Bio breidt kantoorruimte uit in New Jersey met belangrijke wijzigingJune 4, 2025 | nl.investing.comTevogen Bio breidt AI-initiatief uit voor ontwikkeling immunotherapieJune 1, 2025 | nl.investing.comTevogen Bio Holdings Inc. (NASDAQ:TVGN) Sees Significant Drop in Short InterestJune 1, 2025 | marketbeat.comTevogen Bio Holdings Inc. Unveils Tevogen.AI™ Initiative to Enhance Immunotherapy Development with Advanced AI TechnologiesMay 30, 2025 | quiverquant.comTevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks PartnershipsMay 30, 2025 | globenewswire.comTevogen Bio (NASDAQ:TVGN) Earns "Buy" Rating from D. Boral CapitalMay 28, 2025 | marketbeat.comTevogen Peports Plans to Increase the Target Population for TVGN 489May 26, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBHSE, TVGN, FENC, and GNFT Company DescriptionsBull Horn NASDAQ:BHSEBull Horn Holdings Corp. does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the sports, entertainment, and brands sectors. The company was incorporated in 2018 and is based in Miami Beach, Florida.Adherex Technologies NASDAQ:FENC$7.76 -0.10 (-1.27%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$7.81 +0.05 (+0.64%) As of 06/20/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.GENFIT NASDAQ:GNFT$3.88 -0.16 (-3.84%) As of 06/20/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Semper Paratus Acquisition NASDAQ:TVGN$1.20 0.00 (0.00%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.22 +0.02 (+1.25%) As of 06/20/2025 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
